Cost-effectiveness of liquid-based cytology with or without hybrid-capture II HPV test compared with conventional Pap smears: A study by the French society of clinical cytology

2005 ◽  
Vol 33 (5) ◽  
pp. 338-343 ◽  
Author(s):  
Béatrix Cochand-Priollet ◽  
Isabelle Cartier ◽  
Patricia de Cremoux ◽  
Catherine Le Galès ◽  
Marianne Ziol ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Pap Smears ◽  
French Society ◽  
Hybrid Capture ◽  
Hpv Test ◽  
Liquid Based Cytology

Cost-Effectiveness of Liquid-Based Cytology with or without Hybrid-Capture II HPV Test Compared with Conventional Pap Smears

2006 ◽  
Vol 10 (2) ◽  
pp. 129
Author(s):  
B Cochand-Priollet ◽  
I Cartier ◽  
P de Cremoux ◽  
C Le Gales ◽  
M Ziol ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Pap Smears ◽  
Hybrid Capture ◽  
Hpv Test ◽  
Liquid Based Cytology

scholarly journals Experience in the use of modern H-SIL diagnostic methods in the screening of cervical cancer on the example of the Rostov region

2019 ◽  
Vol 10 (1) ◽  
pp. 28-34
Author(s):  
Tatiana A. Dimitriadi ◽  
Dmitry V. Burtsev ◽  
Elena A. Dzhenkova ◽  
Alexander F. Mikhelson ◽  
Elizaveta Yu. Lebedenko
Keyword(s):  
Cervical Cancer ◽  
Screening Program ◽  
Video Recording ◽  
Diagnostic Methods ◽  
Pap Smears ◽  
Rostov Region ◽  
Cancer Screening Program ◽  
Hpv Test ◽  
Cervical Cancer Screening Program ◽  
Liquid Based Cytology

Objective: to evaluate the eff ectiveness of the regional cervical cancer screening program by liquid-based cytology. Materials and Methods: the geography of screening includes 54 medical units of the Rostov region, where patients are taken swabs from the cervix. HPV positive patients with abnormal PAP smears are invited to the Regional cervical pathology center for diagnosis and treatment. Methods. liquid-based cytology, the HPV test RealTime PCR, colposcopy with video recording, biopsy of the cervix by the method of loop excision or electroradiographic conization. Results: From 2014 to 2017, 188 641 cytology tests were performed. Cervical cancer was revealed in 189 women – (0.1 %), H-SIL and ASCH in 566 (0.3 %), 377 ASCUS (0.2 %), L-SIL in 23014 (12.2 %), absence of intracellular lesions or malignancy in 164495 (87.2 %). 2162 HPV-positive women aged 18 to 69 years were invited to the Regional cervical pathology center gynecologist for examination. Treatment by conization (622) and excision (830) of the cervix was performed in 1452 patients, H-SIL and CIS were revealed in 1162 women (78 %). Conclusion: tests such as liquid-based cytology and HPV testing, their optimal multiplicity and sequence allow timely detection and treatment of precancerous cervical epithelium lesions.

Performance of self-sampled HPV test in comparison with liquid based cytology

2014 ◽  
Vol 177 ◽  
pp. 72-76 ◽  
Author(s):  
Sarah Igidbashian ◽  
Sara Boveri ◽  
Davide Radice ◽  
Chiara Casadio ◽  
Noemi Spolti ◽  
...  
Keyword(s):  
Hpv Test ◽  
Liquid Based Cytology

Pap Test Reporting Rates for Conventional Smear and Liquid-Based Cervical Cytology from the Largest Academic Women's Hospital in China: Analysis of 1,248,785 Pap Test Reports

2015 ◽  
Vol 59 (6) ◽  
pp. 445-451 ◽  
Author(s):  
Xiang Tao ◽  
R. Marshall Austin ◽  
Hao Zhang ◽  
Lihong Zhang ◽  
Jianan Xiao ◽  
...  
Keyword(s):  
Cervical Screening ◽  
Pap Test ◽  
Major Change ◽  
Cervical Cytology ◽  
Pap Smears ◽  
Pap Tests ◽  
Bethesda System ◽  
Liquid Based Cytology ◽  
The Bethesda System ◽  
Reporting Rates

Objective: The Obstetrics and Gynecology Hospital of Fudan University (OGHFU) in Shanghai is the largest academic women's hospital in China. Between 2009 and 2014, the use of liquid-based cytology (LBC) significantly increased while gradually adopting the Bethesda System (TBS), and in 2012 local regulations mandated that pathologists replace technicians to sign out Pap tests. Design: A retrospective OGHFU database search documented all Pap test reports between 2009 and 2014 by specimen type, either LBC or conventional Pap smears (CPS), and final reporting category. A total of 1,224,785 Pap reports were analyzed to document variations in Pap test reporting during a period of major change in cervical screening in China. Results: LBC gradually replaced CPS, which declined from over 65% of Pap tests in 2010 to 6.4% in 2014. Of 514,811 Pap reports using the traditional class system, class I (negative) reports accounted for 98.3% of results. With the introduction of TBS reporting, pathologist reviews and substantial replacement of CPS by LBC, the laboratory abnormal Pap test rate increased significantly to almost 5%. Conclusions: Changes in cervical cytology reporting between 2009 and 2014 in China's largest academic women's hospital reflected both increased use of LBC and the introduction of pathologist TBS reporting. Abnormality rates increased significantly and fell within CAP benchmark ranges.

Novaprep® Vial Test is a suitable liquid-based cytology medium for high risk human papillomavirus testing by Hybrid Capture 2

2010 ◽  
Vol 49 (4) ◽  
pp. 286-289 ◽  
Author(s):  
Jean-Luc Prétet ◽  
Chrystelle Vidal ◽  
Karine Le Bail Carval ◽  
Rajeev Ramanah ◽  
Xavier Carcopino ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Hybrid Capture ◽  
Human Papillomavirus Testing ◽  
Hybrid Capture 2 ◽  
Liquid Based Cytology

scholarly journals Organised screening for cervical cancer in France: a cost-effectiveness assessment

BMJ Open ◽  
2017 ◽  
Vol 7 (10) ◽  
pp. e014626 ◽  
Author(s):  
Stéphanie Barré ◽  
Marc Massetti ◽  
Henri Leleu ◽  
Frédéric De Bels
Keyword(s):  
Cervical Cancer ◽  
Cost Effectiveness ◽  
Cost Saving ◽  
Pap Test ◽  
Participation Rate ◽  
Screening Tests ◽  
Lifetime Horizon ◽  
Effective Strategies ◽  
Hpv Test ◽  
Effectiveness Assessment

ObjectiveAccording to the third cancer plan, organised screening (OS) of cervical cancer (CC) among women aged 25–65 years should be implemented in France in the forthcoming years. The most efficient way to implement OS in the French healthcare system is yet to be determined.MethodsA microsimulation model was developed adopting a collective ‘all payers’ perspective. A closed cohort of women eligible for CC screening and representative in terms of age and participation in individual screening (IndScr) by annual Papanicolaou (Pap) testing every 3 years was modelled on a lifetime horizon. Different OS strategies, additive to IndScr with a 61.9% participation rate based on mailed invitations to non-participant women to perform OS were assessed. Similar modalities were applied to OS and IndScr participants. Strategies implied different screening tests (Papanicolaou (Pap) test, human papillomavirus (HPV) test and p16/Ki67 double staining) and OS periodicity.ResultsCompared with IndScr only, all OS strategies were associated with decreased cancer incidence/mortality (from 14.2%/13.5% to 22.9%/25.8%). Most strategies generated extra costs ranging from €37.9 to €1607 per eligible woman. HPV testing every 10 and 5 years were cost saving. HPV tests every 10 and 5 years were the most efficient strategies, generating more survival at lower costs than Pap-based strategies. Compared to IndScr only, an HPV test every 10 years was cost saving. The most effective strategies were p16/Ki67 as primary or HPV positive confirmation tests, with respective incremental cost-effectiveness ratios of €6 541 250 and €101 391 per life year. Pap-based strategies generated intermediary results.ConclusionOS strategies based on the HPV test appear highly efficient. However, our results rely on the assumption that women and practitioners comply with the recommended OS periodicities (3, 5, 10 years). Implementing these OS modalities will require major adaptations to the current CC screening organisation. Pap test-based strategies might be simpler to setup while preparing an appropriate implementation of more efficient OS screening modalities.

scholarly journals Comparison of Clinical Performance of Abbott RealTime High Risk HPV Test with That of Hybrid Capture 2 Assay in a Screening Setting

2011 ◽  
Vol 49 (4) ◽  
pp. 1446-1451 ◽  
Author(s):  
F. M. Carozzi ◽  
E. Burroni ◽  
S. Bisanzi ◽  
D. Puliti ◽  
M. Confortini ◽  
...  
Keyword(s):  
High Risk ◽  
Clinical Performance ◽  
Hybrid Capture ◽  
Hpv Test ◽  
Hybrid Capture 2 ◽  
High Risk Hpv

PP62 Cost-Effectiveness Of Cervical Cancer Screening In Estonia

2019 ◽  
Vol 35 (S1) ◽  
pp. 49-49
Author(s):  
Triin Võrno ◽  
Kaja-Triin Laisaar ◽  
Terje Raud ◽  
Kai Jõers ◽  
Doris Meigas-Tohver ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Screening Program ◽  
Pap Test ◽  
Cancer Screening Program ◽  
Hpv Test ◽  
Cervical Cancer Screening Program ◽  
The Cost

IntroductionIn Estonia, organized cervical cancer screening program is targeted at women aged 30–55(59) years and Pap-tests are taken every five years. Since cervical cancer is associated with human papillomavirus (HPV), a number of countries have introduced the HPV-test as the primary method of screening. The objective of this study was to evaluate the cost-effectiveness of organized cervical cancer screening program in Estonia by comparing HPV- and Pap-test based strategies.MethodsFor the cost-effectiveness analysis, a Markov cohort model was developed. The model was used to estimate costs and quality-adjusted life-years (QALYs) of eight screening strategies, varying the primary screening test and triage scenarios, upper age limit of screening, and testing interval. Incremental cost-effectiveness ratios (ICERs) were calculated in comparison to current screening practice as well as to the next best option. Sensitivity analysis was performed by varying one or more similar parameter(s) at a time, while holding others at their base case value. The analysis was performed from the healthcare payer perspective adopting a five percent annual discount rate for both costs and utilities.ResultsIn the base-case scenario, ICER for HPV-test based strategies in comparison to the current screening practice was estimated at EUR 8,596–9,786 per QALY. For alternative Pap-test based strategies ICER was estimated at EUR 2,332–2,425 per QALY. In comparison to the next best option, HPV-test based strategies were dominated by Pap-test based strategies. At the cost-effectiveness threshold of EUR 10,000 per QALY Pap-testing every three years would be the cost-effective strategy for women participating in the screening program from age 30 to 63 (ICER being EUR 3,112 per QALY).ConclusionsDecreasing Pap-test based screening interval or changing to HPV-test based screening can both improve the effectiveness of cervical cancer screening program in Estonia, but based on the current cost-effectiveness study Pap-test based screening every three years should be preferred.

Liquid-Based Cytology: Evaluation of Effectiveness, Cost-Effectiveness, and Application to Present Practice

2004 ◽  
Vol 2 (6) ◽  
pp. 597-611 ◽  
Author(s):  
J. Thomas Cox
Keyword(s):  
Cost Effectiveness ◽  
Cervical Screening ◽  
Pap Test ◽  
Representative Specimen ◽  
Low Grade ◽  
High Grade ◽  
Squamous Intraepithelial Lesion ◽  
Split Sample ◽  
Intraepithelial Lesion ◽  
Liquid Based Cytology

This article reviews the data available as of 2004 on the effectiveness and cost-effectiveness of cervical screening with the two available cytologic methods, the conventional Papanicolaou (Pap; CP) smear and liquid-based cytology (LBC), and discusses the application of LBC to current practice. The majority of LBC studies are on the ThinPrep Pap Test (CYTYC, Boxsborough, MA) and the remainder are on SurePath (TriPath, Burlington, NC), which was previously known as AutoCyte Prep. LBC identified more low-grade squamous intraepithelial lesion (LSIL) Pap test results compared with paired conventional cytology in 17 of 21 ThinPrep and 9 of 12 SurePath “split-sample” studies considered to fulfill the criteria for inclusion in the British NHS Health Technology Assessment (HTA) evaluation of cervical cytology. In four of the six recent ThinPrep and one of two SurePath split-sample studies, more high-grade squamous intraepithelial lesion-positive (HSIL+) results were identified by LBC than by CP. All 15 “direct-to vial studies” meeting HTA criteria reported more LSIL+ results for LBC compared with CP, and all eight of the direct-to-vial studies reporting HSIL+ results separately showed increased detection of high-grade cytology interpretations. Fifteen studies met the criteria for evaluating sensitivity and specificity. Aggregate sensitivity for the CP was 71.5% and for LBC was 80.1%. Indirect comparisons of the two LBC methods did not detect a difference in sensitivity, and a meta-analysis of the six studies comparing specificity between CP and LBC found no difference. Other capabilities of LBC are improved specimen adequacy and the ability to do ancillary testing out of the liquid-based vial. In cost-effective analyses based on models of disease natural history and/or the clinical effectiveness of each screening modality, screening with CP was always dominated by screening with LBC. Primary cervical screening guidelines issued by the American Cancer Society in 2002 recommend repeating the cytology biannually if liquid-based and annually if conventional. The gain in sensitivity, apparent cost-effectiveness, and advantage of having a representative specimen for ancillary testing, support the use of LBC.

Sign in / Sign up

Export Citation Format

Share Document